Member Info for vares

Https://jitc.bmj.com/content/14/6/e015830

Https://www.utupub.fi/server/api/core/bitstreams/8148fd4e-c151-4186-982d-2d3c0c26f6b2/content

Https://www.tipranks.com/stocks/gb:farn?utm_source=msn.com&utm_medium=referral

Https://www.hcplive.com/view/bexmarilimab-safe-and-efficacious-in-treating-myelodysplastic-syndromes-with-amer-zeidan-md

Https://www.tipranks.com/stocks/gb:farn?utm_source=msn.com&utm_medium=referral

Https://www.tipranks.com/stocks/gb:farn?utm_source=msn.com&utm_medium=referral

Https://www.youtube.com/watch?v=WXq66K2-iQQ

Https://www.youtube.com/watch?v=WXq66K2-iQQ

Https://www.youtube.com/watch?v=WXq66K2-iQQ

Https://www.msn.com/en-us/health/other/study-advances-cancer-precision-therapies-by-identifying-patients-who-benefit-from-bexmarilimab-treatment/ar-AA1F9Lzf?apiversion=v2&noservercache=1&domshim=1&renderwebcomponents=1&wcseo=1&batchservertelemetry=1&noservertelemetry=1

Https://www.msn.com/en-us/health/other/study-advances-cancer-precision-therapies-by-identifying-patients-who-benefit-from-bexmarilimab-treatment/ar-AA1F9Lzf?apiversion=v2&noservercache=1&domshim=1&renderwebcomponents=1&wcseo=1&batchservertelemetry=1&noservertelemetry=1

Https://www.msn.com/en-us/health/other/study-advances-cancer-precision-therapies-by-identifying-patients-who-benefit-from-bexmarilimab-treatment/ar-AA1F9Lzf?apiversion=v2&noservercache=1&domshim=1&renderwebcomponents=1&wcseo=1&batchservertelemetry=1&noservertelemetry=1

Https://submit.hematology.org/program/presentation/676454

Https://faron.com/releases-and-publications/faron-hits-key-milestone-with-bexmab-phase-2-completion-advances-to-registrational-trial-with-fda-alignment/

Timo is not "as chairman of faron..

Https://faron.com/releases-and-publications/updated-bexmab-phase-i-ii-data-presented-at-esmo-2025-shows-further-improvement-strengthening-the-clinical-profile-of-bexmarilimab-in-treatment-naive-hr-mds-patients/

Results

Combination treatment induced immune activation in the BM, with a mean increase of 87% in monocyte HLA-DR expression, reflecting antigen presentation capacity and 25% increase of BM CD8+ T cells, already after cycle 1. Single-cell RNA sequencing of bone marrow samples from responding patients revealed extensive remodelling of the myeloid compartment, including a reduction in immature monocytes and GMP-like cells. Gene-set enrichment analysis indicated suppression of oxidative phosphorylation in blasts, suggesting a direct metabolic effect. These findings support a dual mechanism of action: immune-mediated activation and direct modulation of blast metabolism. In addition to these translational results, full pharmacokinetic (PK) and pharmacodynamic (PD, including correlation with clinical response) data will be presented for the first time.

Conclusions

Together, the clinical and biological findings highlight bexmarilimab’s potential as a novel therapeutic strategy for HR MDS and support its advancement into phase 3.

Copy from Finnish forum:

Quote from ESMO’s website:

https://www.esmo.org/meeting-calendar/esmo-congress-2025/press-media

* “All regular abstracts accepted for presentation at the ESMO Congress 2025 as Proffered Paper (suffix O), Mini Oral (suffix MO), Poster (suffix P or TiP), ePoster (suffix eP or eTiP), EONS abstracts (prefix CN), will be published online via the ESMO website at 00:05 CEST on Monday, 13 October 2025.”

It is Mini Oral Abstract Session 1249MO

So, we’ll see something tomorrow.

It is much easier if you dig e.g. Yahoo chart: https://finance.yahoo.com/quote/FARN.L/

Https://myeloid-directed-therapies.com/speaker/maija-hollmen/